SERZYL 25 µg/1 doza+ 125 µg/1 doza suspenzija za inhalaciju pod pritiskom Bòsnia i Hercegovina - croat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

serzyl 25 µg/1 doza+ 125 µg/1 doza suspenzija za inhalaciju pod pritiskom

viatris bh d.o.o. - flutikazon, Салметерол - suspenzija za inhalaciju pod pritiskom - 25 µg/1 doza+ 125 µg/1 doza - 1 doza suspenzije za inhalaciju pod pritiskom sadrži: 25 mcg salmeterola (u obliku salmeterol ksinafoata) 125 mcg flutikazona (u obliku flutikazon propionata)

SERZYL 25 µg/1 doza+ 250 µg/1 doza suspenzija za inhalaciju pod pritiskom Bòsnia i Hercegovina - croat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

serzyl 25 µg/1 doza+ 250 µg/1 doza suspenzija za inhalaciju pod pritiskom

viatris bh d.o.o. - flutikazon, Салметерол - suspenzija za inhalaciju pod pritiskom - 25 µg/1 doza+ 250 µg/1 doza - 1 doza suspenzije za inhalaciju pod pritiskom sadrži: 25 mcg salmeterola (u obliku salmeterol ksinafoata) i 250 mcg flutikasona (u obliku flutikazon propionata)

Xofluza Unió Europea - croat - EMA (European Medicines Agency)

xofluza

roche registration gmbh - baloxavir marboxil - gripa, ljudska - antivirusni lijekovi za sustavnu uporabu - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

BONVIVA 150 mg/1 tableta film tableta Bòsnia i Hercegovina - croat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

bonviva 150 mg/1 tableta film tableta

medicopharmacia d.o.o. sarajevo - ibandronska kiselina - film tableta - 150 mg/1 tableta - 1 film tableta sadrži: 150 mg ibandronska kiselina (u obliku ibandronat natrijum monohidrata)

Sitagliptin / Metformin hydrochloride Mylan Unió Europea - croat - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evrenzo Unió Europea - croat - EMA (European Medicines Agency)

evrenzo

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemijski pripravci - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Clopidogrel/Acetylsalicylic acid Teva Unió Europea - croat - EMA (European Medicines Agency)

clopidogrel/acetylsalicylic acid teva

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - kombinacije - klopidogrel/acetilsalicilna kiselina teva je indiciran za prevenciju aterotrombotskih događaja u odraslih bolesnika koji već uzimaju klopidogrel i acetilsalicilnu kiselinu (ask). Клопидогрел/Ацетилсалициловая kiselina tewa je fiksna kombinacija doza lijekova za nastavak terapije:ne porast segmenta st akutna koronarna sindrom (nestabilna angina, ili ne‑q‑infarkt miokarda), uključujući i bolesnike koji su patili стентирование nakon чрескожных koronarnih interventionst porast u segmentu akutnog infarkta miokarda u liječenju pacijenata koji imaju pravo na thrombolytic terapije.

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Unió Europea - croat - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

LIPERTANCE 10 mg/1 tableta+ 5 mg/1 tableta+ 5 mg/1 tableta filmom obložena tableta Bòsnia i Hercegovina - croat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lipertance 10 mg/1 tableta+ 5 mg/1 tableta+ 5 mg/1 tableta filmom obložena tableta

oktal pharma d.o.o. sarajevo - amlodipin, atorvastatin, Периндоприл - filmom obložena tableta - 10 mg/1 tableta+ 5 mg/1 tableta+ 5 mg/1 tableta - jedna filmom obložena tableta sadrži: 10 mg atorvastatina (što odgovara 10,82 mg atorvastatin kalcij trihidrata), 5 mg perindopril arginina (što odgovara 3,40 mg perindoprila) i 5 mg amlodipina (što odgovara 6,94 mg amlodipin besilata)

LIPERTANCE 20 mg/1 tableta+ 5 mg/1 tableta+ 5 mg/1 tableta filmom obložena tableta Bòsnia i Hercegovina - croat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lipertance 20 mg/1 tableta+ 5 mg/1 tableta+ 5 mg/1 tableta filmom obložena tableta

oktal pharma d.o.o. sarajevo - amlodipin, atorvastatin, Периндоприл - filmom obložena tableta - 20 mg/1 tableta+ 5 mg/1 tableta+ 5 mg/1 tableta - jedna filmom obložena tableta sadrži: 20 mg atorvastatina (što odgovara 21,64 mg atorvastatin kalcij trihidrata), 5 mg perindopril arginina (što odgovara 3,40 mg perindoprila) i 5 mg amlodipina (što odgovara 6,94 mg amlodipin besilata)